


23. (New) A method for inhibiting replication of a virus of an HIV strain that is resistant to a chemotherapeutic agent, the method comprising:
contacting the resistant virus with an amount of a compound effective to inhibit replication of the virus,

wherein the compound is of the formula:




wherein x is: 2,5-OMe or *o*-F.

24. (New) The method of claim 23, wherein the chemotherapeutic agent is Delavirdine, Nevirapine, Efavirenz, Trogidone, AZT, or MKC-442.

25. (New) A method for inhibiting replication of an HIV having a mutation of an amino acid at position 106 or 183 of reverse transcriptase, the method comprising:
contacting the HIV with an amount of a compound effective to inhibit replication of the HIV,

wherein the compound is of the formula:




wherein x is: 2,5-OMe or *o*-F.

26. (New) A method for inhibiting replication of an HIV having one or more of the following amino acid substitutions in reverse transcriptase : L100I, K103N, V106A, E138K, Y181C, or Y188H; the method comprising:

contacting the HIV with an amount of a compound effective to inhibit replication of the HIV,

wherein the compound is of the formula:


DI
cmt



wherein x is: 2,5-OMe or *o*-F.

27. (New) A method for inhibiting replication of a virus of an HIV strain that is resistant to a non-nucleoside inhibitor-resistant strain of HIV; the method comprising contacting the resistant virus with an amount of a compound effective to inhibit replication of the virus,

wherein the compound is of the formula:




wherein x is: 2,5-OMe or *o*-F.

28. (New) A method of inhibiting replication of a virus of an HIV strain selected from the group consisting of RT-MDR, HIV A17, and HIV A17 variant; the method comprising:


contacting the virus with an amount of a compound effective to inhibit replication of the virus

wherein the compound is of the formula:




wherein x is: 2,5-OMe or *o*-F.

29. (New) The method of claim 23, wherein the compound is




30. (New) The method of claim 25, wherein the compound is




DL
Cmt


31. (New) The method of claim 26, wherein said compound is



32. (New) The method of claim 27, wherein the compound is




33. (New) The method of claim 28, wherein the compound is




Df
amt


34. (New) The method of claim 23, wherein said compound is



35. (New) The method of claim 25, wherein the compound is




36. (New) The method of claim 26, wherein the compound is




DLT
CMT

37. (New) The method of claim 27, wherein the compound is



38. (New) The method of claim 28, wherein the compound is



39. (New) The method of claim 23, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.

40. (New) The method of claim 24, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.

41. (New) The method of claim 25, wherein the replication of the HIV is inhibited within a human peripheral blood mononuclear cell.

DL
cmf
42. (New) The method of claim 26, wherein the replication of the HIV is inhibited within a human peripheral blood mononuclear cell.

43. (New) The method of claim 27, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.

44. (New) The method of claim 28, wherein the replication of the virus is inhibited within a human peripheral blood mononuclear cell.
